BloodStream™ Media

Show notes:

Presenting a NEW BloodLine podcast, “FVIII Inhibitors: The Next Chapter.” In our second episode, we learn about the ten-year journey to bring HEMLIBRA® (emicizumab-kxwh) to market and take a deep look at the clinical trials of HEMLIBRA.

“FVIII Inhibitors: The Next Chapter” is a three-part podcast series looking at the current and future state of living with hemophilia A with factor VIII inhibitors.

Special, huge thanks to our guests:

Justin Levesque

Dr. Guy Young

Sue Geraghty

Liz Purvis

Eric Lowe

Janet Brewer

and Benjamin Denman

BloodLine—FVIII Inhibitors: The Next Chapter is produced by me, Patrick James Lynch, and Ryan Gielen. Written by Ryan Gielen. Edited by Josh Davis. Produced at BloodStream Media's Los Angeles studio, and mixed by Michael Capuano at Icemen Sound.

For more information on the podcast, visit our website at www.BloodLinePod.com.

This series was produced by Believe Limited in collaboration with Genentech, the makers of HEMLIBRA® (emicizumab-kxwh).

What is HEMLIBRA?

HEMLIBRA is a prescription medicine used for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children, ages newborn and older, with hemophilia A with or without factor VIII inhibitors.

What is the most important information I should know about HEMLIBRA?

HEMLIBRA increases the potential for your blood to clot. Carefully follow your healthcare provider’s instructions regarding when to use an on-demand bypassing agent or factor VIII, and the dose and schedule to use for breakthrough bleed treatment. HEMLIBRA may cause serious side effects when used with activated prothrombin complex concentrate (aPCC; FEIBA®), including thrombotic microangiopathy (TMA), and blood clots (thrombotic events). If aPCC (FEIBA®) is needed, talk to your healthcare provider in case you feel you need more than 100 U/kg of aPCC (FEIBA®) total.

How should I use HEMLIBRA?

Stop (discontinue) prophylactic use of bypassing agents the day before starting HEMLIBRA prophylaxis.

• You may continue prophylactic use of factor VIII for the first week of HEMLIBRA prophylaxis.

What should I know about lab monitoring?

HEMLIBRA may interfere with laboratory tests that measure how well your blood is clotting and may cause a false reading. Talk to your healthcare provider about how this may affect your care.

The most common side effects of HEMLIBRA include: redness, tenderness, warmth, or itching at the site of injection; headache; and joint pain.

These are not all of the possible side effects of HEMLIBRA. Speak to your healthcare provider for medical advice about side effects.

You may report side effects to the FDA at (800) FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at (888) 835-2555.

Please see the HEMLIBRA full Prescribing Information and Medication Guide for Important Safety Information, including Serious Side Effects, here: bit.ly/2kp959s

HEMLIBRA® is a registered trademark of Chugai Pharmaceutical Co., Ltd., Tokyo, Japan. The Genentech logo is a registered trademark of Genentech, Inc. © 2019 Genentech USA, Inc. All rights reserved. EMI/053019/0107e 07/19